SEC Form 4 · accession 0001250853-18-000074
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Officer — President and CEO · Director · 10% Owner
Period of report
May 7, 2018
Accepted (ET)
May 9, 2018 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF2 | May 7, 2018 | S | 1,730 | $10.01 | D | 2,244,341 | D | |
| COMMON STOCK | May 9, 2018 | S | 200 | $10.00 | D | 2,244,141 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.15, inclusive.